Document is current
Any future updates will be listed below
-
Authors
Moral-Sanz, Javier https://orcid.org/0000-0001-8602-8554
Fernández-Carrasco, Isabel
Ramponi, Valentina
Garrido, Amanda https://orcid.org/0000-0003-3140-3251
Karbat, Izhar
Cabezas-Sainz, Pablo
Rivera-de-Torre, Esperanza https://orcid.org/0000-0002-0272-6150
Elsallabi, Osama
Martín-Hernández, Roberto
López-Aceituno, José L.
Price, Nathan L. https://orcid.org/0000-0002-2821-9608
Sanchez, Laura https://orcid.org/0000-0001-7927-5303
Colmenarejo, Gonzalo
Martínez-del-Pozo, Álvaro https://orcid.org/0000-0003-0043-5939
Vetter, Irina
Cogolludo, Angel
Perez-Vizcaino, Francisco
Del-Pozo, Jorge https://orcid.org/0000-0002-9582-1228
Reuveny, Eitan https://orcid.org/0000-0003-4945-9683
Fernández-Rojo, Manuel A. https://orcid.org/0000-0002-2240-1951
Robbins, Paul D. https://orcid.org/0000-0003-1068-7099
de Cabo, Rafael https://orcid.org/0000-0002-3354-2442
Serrano, Manuel https://orcid.org/0000-0001-7177-9312
Ikonomopoulou, Maria P. https://orcid.org/0000-0001-7739-080X
- License Information
-
More Information
Article History
Received: 21 December 2023
Accepted: 31 October 2025
First Online: 12 January 2026
Competing interests
: M.P.I., J.M.-S., M.S. V.R., I.F.-C. and M.A.F.-R. are named inventors in a filed patent related to senolytic therapies (WO 2025/016917 A1). M.S. is a shareholder of Senolytic Therapeutics, Inc., Life Biosciences, Inc., Rejuveron Senescence Therapeutics, AG, and Altos Labs, Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper. The other authors declare no competing interests.
